We looked at and reviewed the charts of Halozyme Therapeutics (HALO) on December 23 and wrote: "Continue to hold long positions but raise stop protection to $38 from $35. $48 and then $55 are our price targets."
More from Investing
Monday turns uninspiring as traders lack incentive to buy and oil moves higher amid poor economic data.
A rally back to this area could unfold soon, so current investors should keep a tight leash on shares.
Here's our first price target and our long term objective.
Econ 101 suggests that at some point, either the supply side catches up, or demand falls to get prices back in equilibrium. Let's see what this means for oil -- and a potential recession.